Myriad Genetics Q1 revenue growth misses estimates

Myriad Genetics

05/05/2026 21:35

Overview

Molecular diagnostic test maker's Q1 revenue rose 2% yr/yr, missing analyst expectations

Adjusted EPS for Q1 was a loss, missing analyst expectations

Company saw stable test volumes, with declines in Prenatal Health offset by growth in Cancer Care and Mental Health

Outlook

Myriad Genetics sees full-year 2026 revenue of $860 mln to $880 mln

Company expects 2H 2026 revenue to be greater than 1H 2026

Myriad Genetics projects full-year 2026 adjusted EBITDA of $37 mln to $49 mln

Result Drivers

CANCER CARE GROWTH - 13% yr/yr test volume growth in Cancer Care Continuum drove segment revenue higher, supported by dedicated sales efforts

MENTAL HEALTH GAINS - 7% yr/yr test volume growth and improved reimbursement trends boosted Mental Health segment revenue

PRENATAL HEALTH DECLINE - 12% yr/yr drop in Prenatal Health test volume weighed on results, with company citing ongoing disruption from new order management system

Company press release: ID:nGNX7pvY1S

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$200.40 mln
$202.48 mln (12 Analysts)
Q1 Adjusted EPS
Miss
-$0.09
-$0.07 (12 Analysts)
Q1 EPS
-$0.36
Q1 Net Income
-$34.10 mln
Q1 Gross Margin
68.70%
Q1 Adjusted Operating Expenses
$148.50 mln
Q1 Operating Expenses
$168.30 mln
Q1 Operating Income
-$30.70 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 7 "hold" and 3 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Myriad Genetics Inc is $6.00, about 21.5% above its May 4 closing price of $4.94

The stock recently traded at 68 times the next 12-month earnings vs. a P/E of 102 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)